At Trinity, we’ve worked on tactical solutions to position our clients for success.

CASE STUDY: Maximizing a product’s value


For this top 5 global pharma company, we worked to answer questions about the target market, key value drivers, and how to maximize the product’s value.


  • The client was a top 5 global pharma company
  • The company’s recently launched short-acting pain product was performing below expectations, raising questions about proper target market definition, key value drivers, and how to maximize the product’s value along with its long-acting version (about to be launched)




Trinity performed a comprehensive set of analyses to address the client’s needs

  • Analysis of claims of 400K+ pain patients in the United Healthcare claims database to develop a detailed understanding of the pain market
  • Using IMS, NPA, Xponent, SDI, PlanTrak datasets to analyze current performance of the product with respect to:
    • Physician switching behavior
    • Prescribing by promotional targets, and promotional effectiveness
    • Prescribing by plan type
  • Conducting a survey of 600+ pain treaters, simulating over 24,000 unique treatment events
  • Analysis of dozens of analogs to derive the most realistic uptake curve for the product
  • Building a detailed monthly forecast accounting for both the short- and long-acting version of the product and their interaction on the market


Project highlights

  • Trinity utilized a variety of approaches to analyze this complex market



Trinity provided the client with a completely redefined robust understanding of the complex and challenging pain market, including the positioning and forecast for its products

  • Trinity’s insights completely redefined and refocused the client’s view of the pain marketplace
  • Trinity’s analysis of key market characteristics provided the client with actionable key drivers for revenue growth, leading to immediate realignment of the client’s marketing strategy for the product
  • Trinity provided the client with a data-driven view of how the short-acting and long-acting pain products can be expected to interact on the market
  • The client received a substantially revised, more realistic forecast based on robust primary and secondary research